Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Filings · News reference
Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock
Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales Agreement,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSMPDUFA target action date set for June 29, 2027
Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals
On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Agreement") with Hovione FarmaCiencia S.A. ("Hovione") to manufacture bezuclastinib